BRCA1 and ovarian cancer: Since the degree and duration of response to PARP inhibitors are greatest in ovarian cancer patients who have mutations in DNA repair enzymes (BRCA1/2 and others), the ability of SFXN4 inhibition to simultaneously disable multiple DNA repair pathways suggests that targeting SFXN4 has the potential to extend the excellent response to PARP inhibitors to women without defects in DNA repair enzymes.